Skip to main content
Premium Trial:

Request an Annual Quote

NIPD Firm KellBenX Raises $10M in Series C Round

NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.

The financing was raised by a new investor that Bennani declined to identify, and will be used to accelerate clinical trials for its technology. Since its inception, it has raised $15 million.

The Great River, NY-based company, founded in 2010, is building a blood-based assay that can separate rare fetal cells in maternal blood. Its technology is based on antibody called 4B9 licensed from AdnaGen. 4B9 recognizes and binds to an epitope expressed by a type of nucleated fetal nucleated red blood cell, or fNRBC.

KellBenX plans to launch its test in late 2014 or early 2015.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.